PMID- 23944651
OWN - NLM
STAT- MEDLINE
DCOM- 20140429
LR  - 20140312
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 54
IP  - 3
DP  - 2014 Mar
TI  - Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are 
      simultaneously oversecreted in platelet components associated with acute 
      transfusion reactions.
PG  - 613-25
LID - 10.1111/trf.12378 [doi]
AB  - BACKGROUND: Leukoreduction of labile blood components dramatically decreases the 
      frequency of minor, intermediate, and severe adverse events (AEs), referred to as 
      acute transfusion reactions (ATRs), especially after transfusion of platelet 
      components (PCs). The pathophysiology of AEs may result from accumulation of 
      soluble, secreted, platelet (PLT) factors with proinflammatory functions stored 
      in PCs. Thus, several cosynergizing factors associated with PLT accumulation in 
      PCs may contribute to clinically reported ATRs with inflammatory symptoms. STUDY 
      DESIGN AND METHODS: We screened for 65 PLT-associated secretory products in PCs 
      that caused ATRs and identified PLT molecules associated with ATRs and 
      inflammation. A functional in vitro study using PC supernatants assayed on 
      reporting immune cells was performed to indicate relevance. RESULTS: Among 10,600 
      apheresis PCs, 30 caused inflammatory ATRs and contained significantly elevated 
      levels of soluble CD40 ligand (sCD40L), interleukin (IL)-27, and soluble OX40 
      ligand (sOX40L). Normal PLTs secreted IL-27 and sOX40L at bioactive 
      concentrations upon thrombin stimulation and were up regulated in association 
      with ATRs, similar to sCD40L. Other secreted products were identified but not 
      investigated further as their positivity was not consistent. CONCLUSIONS: This 
      study demonstrates the putative participation of PLT-derived sOX40L, IL-27, and 
      sCD40L, which accumulate in PC supernatants, with inflammatory-type ATRs. Further 
      studies are required to determine the clinical significance of these findings to 
      forecast preventive measures whenever possible.
CI  - (c) 2013 American Association of Blood Banks.
FAU - Hamzeh-Cognasse, Hind
AU  - Hamzeh-Cognasse H
AD  - Universite de Lyon, Saint-Etienne, France.
FAU - Damien, Pauline
AU  - Damien P
FAU - Nguyen, Kim Anh
AU  - Nguyen KA
FAU - Arthaud, Charles-Antoine
AU  - Arthaud CA
FAU - Eyraud, Marie-Ange
AU  - Eyraud MA
FAU - Chavarin, Patricia
AU  - Chavarin P
FAU - Absi, Lena
AU  - Absi L
FAU - Osselaer, Jean-Claude
AU  - Osselaer JC
FAU - Pozzetto, Bruno
AU  - Pozzetto B
FAU - Cognasse, Fabrice
AU  - Cognasse F
FAU - Garraud, Olivier
AU  - Garraud O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130814
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Immunologic Factors)
RN  - 0 (Interleukin-27)
RN  - 0 (OX40 Ligand)
RN  - 147205-72-9 (CD40 Ligand)
SB  - IM
MH  - Blood Platelets/immunology/*metabolism
MH  - CD40 Ligand/*metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Immunologic Factors/metabolism
MH  - Interleukin-27/*metabolism
MH  - OX40 Ligand/*metabolism
MH  - Platelet Transfusion/*adverse effects
EDAT- 2013/08/16 06:00
MHDA- 2014/04/30 06:00
CRDT- 2013/08/16 06:00
PHST- 2013/06/08 00:00 [received]
PHST- 2013/06/10 00:00 [accepted]
PHST- 2013/08/16 06:00 [entrez]
PHST- 2013/08/16 06:00 [pubmed]
PHST- 2014/04/30 06:00 [medline]
AID - 10.1111/trf.12378 [doi]
PST - ppublish
SO  - Transfusion. 2014 Mar;54(3):613-25. doi: 10.1111/trf.12378. Epub 2013 Aug 14.